Kalos Therapeutics, Inc. Awarded Grant for KT-220 under Qualifying Therapeutic Discovery Project

Nov. 8, 2010 - PRLog -- Kalos is an advanced pre-clinical stage cancer therapeutics company focused on compounds that operate on a new and unique pathway. The company is developing KT-220 synthesized from endogenous peptides that have shown efficacy and safety in man. In animal testing across a broad array of cancers we have seen tumor shrinkage and prolonged control of tumors even after discontinuance of treatment. In previous human trials, KT-220 was effective increasing the elimination of fluid through the kidneys which may result in amelioration of some of the distress caused by the swelling and edema seen in late stage cancers. KT-220 will continue in development under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

Lead Compound

KT-220 is derived from a molecule made in the heart that controls rapid cell growth, like that seen in cancer. KT-220 is a biologic, a protein, that circulates regularly in the body.  By increasing the levels of this naturally occurring compound to therapeutic levels we see a safe non-toxic decrease in excess fluid, and shrinkage of tumors consistent with other approved biologics without the side effects commonly tolerated in patients treated with chemotherapy.“The QDTP Grant ensures San Diego’s’ most innovative companies  like Kalos Therapeutics will be able to maintain their commitment to creating new life changing products for cancer patients,” said George Colberg, Executive Chairman of Kalos Therapeutics, Inc.

To be eligible for the QTDP program, projects must show reasonable potential to result in new therapies to treat areas of unmet medical need; prevent, detect, or treat chronic or acute disease and conditions; reduce long-term health care costs in the United States; or significantly advance the goal of curing cancer within a 30-year period. In addition, preference was given to projects that showed the greatest potential to create and sustain (directly or indirectly) high quality, high-paying jobs in the United States, and advance United States competitiveness in the fields of life, biological, and medical sciences. Projects were reviewed by both the Treasury Department and the Department of Health and Human Services. For more information, please visit the company’s web site at www.kalostpx.com.

Contact:
Kalos Therapeutics, Inc.
George Colberg, Executive Chairman
858-552-6888